Detalhe da pesquisa
1.
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.
Blood
; 128(1): 37-44, 2016 07 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27216216
2.
A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.
Br J Haematol
; 178(4): 547-560, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28466536
3.
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.
Lancet
; 387(10027): 1551-1560, 2016 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-26778538
4.
Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up.
Br J Haematol
; 171(3): 344-54, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26153365
5.
Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma.
Haematologica
; 100(1): 100-6, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25261096
6.
The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit.
Am J Hematol
; 90(5): E86-91, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25651830
7.
Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma.
Haematologica
; 97(12): 1925-8, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-22689676
8.
Adaptive group sequential test with changing patient population.
J Biopharm Stat
; 22(4): 662-78, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22651107
9.
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.
Lancet Oncol
; 12(5): 431-40, 2011 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21507715
10.
Daratumumab With Cetrelimab, an Anti-PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma.
Clin Lymphoma Myeloma Leuk
; 21(1): 46-54.e4, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33485428
11.
Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414).
JTO Clin Res Rep
; 2(2): 100104, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34589982
12.
Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.
Haematologica
; 100(5): e207-10, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25596270
13.
Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials.
Lancet Haematol
; 7(6): e447-e455, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32470437
14.
Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma.
Clin Lymphoma Myeloma Leuk
; 19(5): 275-284, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30795996
15.
Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients With Relapsed or Refractory Multiple Myeloma.
Clin Lymphoma Myeloma Leuk
; 18(1): 44-51, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29054515
16.
Group sequential t-test for clinical trials with small sample sizes across stages.
Contemp Clin Trials
; 28(5): 563-71, 2007 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-17434814
17.
Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma.
J Clin Oncol
; 31(2): 247-55, 2013 Jan 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-23091109
18.
Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma.
Clin Pharmacokinet
; 51(12): 823-9, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23018466
19.
Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphoma.
Clin Pharmacokinet
; 50(12): 781-91, 2011 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22087865
20.
Adaptive group sequential test for clinical trials with changing patient population.
J Biopharm Stat
; 17(6): 1227-38, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-18027228